Company
Every investor coverage indicates participated in a round Fultec raised.
The transaction that ended Fultec's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Bourns Semiconductor Inc | Acquisition | undated | - | anthillonline.com, GBS Ventures |
Companies Fultec acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Fultec. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Venture fund Uniseed led a million-dollar slice of probiotic drinks maker PERKii's four-million-dollar round, its first deal from its new $50 million fund, to fund a national launch.
GBS Ventures reports Novartis has agreed to acquire chronic-pain drug developer Spinifex Pharmaceuticals for US$200 million upfront plus milestones, recalling the company's 2005, 2008 and 2014 venture rounds and its Australian investors.
Also GBS Ventures·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·novartis.com·clinicalleader.com·Brandon Capital portfolio·Startup Daily·Startup Daily·Startup Daily·anthillonline.com·@AuManufacturing·materresearch.org.au·Business News Australia